Who is sponsoring NCT05551221?

NCT05551221 is sponsored by Xintian Pharmaceutical.

What drugs are being tested in NCT05551221?

Interventions in NCT05551221: Silodosin Capsules, Ningmitai capsule, Tamsulosin.

What condition does NCT05551221 study?

NCT05551221 studies Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms.

Is NCT05551221 still recruiting?

NCT05551221 is currently recruiting now. Last updated 23 September 2022.

Last reviewed 2022-09-23 · How we verify

NCT05551221: NQTIPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia

Recruiting now Phase 4 Last updated 23 September 2022

What this trial tests

Phase 4 trial testing Silodosin Capsules in Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms in 312 participants. Currently enrolling.

Timeline

18 July 2022

Primary endpoint
31 December 2023

31 December 2026

Quick facts

Lead sponsor	Xintian Pharmaceutical
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	312
Start date	18 July 2022
Primary completion	31 December 2023
Estimated completion	31 December 2026
Sites	8 locations across China

Drugs / interventions tested

Silodosin Capsules — full drug profile →
Ningmitai capsule — full drug profile →
Tamsulosin (tamsulosin) — full drug profile →

Conditions studied

Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms — all drugs for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms →

Sponsor

Xintian Pharmaceutical — full company profile →

Who can join

Adults 60 to 80, male only, with Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: To evaluate the efficacy and safety of Ningmitai Capsules and Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules. Study design: A multicenter, prospective, randomized, double-blind, positive controlled clinical study. Interventions: Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks. Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

Currently open trials in the same condition.

NCT07416227 — Comparison Between Water Vapor Thermal Therapy and Prostatic Artery Embolization in Treatment of Benign Prostatic Hyperp · NA · recruiting

Other Xintian Pharmaceutical trials

Trials by the same sponsor.

NCT06423235 — Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules · Phase 4 · recruiting
NCT06159114 — Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS · Phase 4 · completed
NCT06064448 — Clinical Observation of Ningmitai Capsule in Treating Chronic Pelvic Pain Syndrome With Erectile Dysfunction · Phase 4 · completed
NCT05890235 — Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome · Phase 4 · completed
NCT06105827 — Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05551221 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xintian Pharmaceutical
Last refreshed: 23 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05551221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing